Generic Name and Formulations:
Cefepime (as HCl) 500mg, 1g, 2g; pwd for IV infusion or IM inj after reconstitution.
Indications for MAXIPIME:
Susceptible infections, including moderate-to-severe pneumonia, uncomplicated skin and skin structure infections, complicated and uncomplicated urinary tract infections (UTIs) including pyelonephritis, complicated intraabdominal in adults (w. metronidazole). Empiric therapy in febrile neutropenia.
When giving IV, infuse over 30mins. Pneumonia: 1–2g IV every 8–12hrs for 10 days. Skin and skin structures, severe UTIs: 2g IV every 12hrs for 10 days. Mild-to-moderate UTIs: 500mg–1g IV or IM every 12hrs for 7–10 days (IM only for UTIs caused by E. coli). Intraabdominal (use w. metronidazole): 2g IV every 8–12hrs for 7–10 days. Febrile neutropenia: 2g IV every 8hrs for 7 days or until neutropenia resolves. CrCl ≤60mL/min: reduce dose; see full labeling. Hemodialysis: give dose after each session. Continuous ambulatory peritoneal dialysis: give usual doses at 48hr intervals.
<2mos: not established. Not for use in serious infection when pathogen is or may be H. influenzae type b. 2mos–16yrs (≤40kg): 50mg/kg/dose every 12hrs (every 8hrs for P. aeruginosa pneumonia); do not exceed recommended adult dose. Severe UTIs, pneumonia, skin and skin structure: give IV for 10 days. Mild-to-moderate UTIs: give IV or IM for 7–10 days (IM only for UTIs caused by E. coli). Febrile neutropenia: give IV every 8hrs for 7 days or until neutropenia resolves.
Penicillin or other β-lactam allergy.
Renal impairment. Risk of neurotoxicity (esp. in renally-impaired); discontinue if occurs and treat appropriately. Renal or hepatic dysfunction, poor nutritional state, prolonged antimicrobial therapy: monitor prothrombin time. History of GI disease (esp. colitis). Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Aminoglycosides may potentiate oto- or nephrotoxicity. Possible nephrotoxicity with diuretics (eg, furosemide). May cause false (+) Coomb's, Clinitest.
Local reactions (eg, pain, phlebitis, inflammation), rash, nausea, vomiting, diarrhea, pruritus, fever, headache, anemia, renal dysfunction; neurotoxicity, C. difficile associated diarrhea, hypersensitivity reactions.
Vials (500mg)—10; 1g, 2g—10, 25
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Ivacaftor Improves Insulin Secretion in Children With Cystic Fibrosis
- Genetic Testing Recommended for Familial Hypercholesterolemia
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry